iShares MSCI ACWI ETF vs Ascendis Pharma A/S — how do they compare? iShares MSCI ACWI ETF trades at $162, while Ascendis Pharma A/S trades at $254.5 (market cap $16.67B). The key difference: iShares MSCI ACWI ETF is trading nearer its 52-week high, Ascendis Pharma A/S nearer its low. Which is the better fit depends on your goals.
| ACWI | ASND | |
|---|---|---|
52-Week High | $161.44 | $277.18 |
52-Week Low | $132.04 | $189.74 |
Market Cap | — | $16.67B |
Sector | — | Health |
Enterprise Value | — | $17.04B |
Trailing returns across standard periods
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →